A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
- PMID: 9920948
- DOI: 10.1056/NEJM199901283400401
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
Abstract
Background: Patients treated with methotrexate for rheumatoid arthritis often improve but continue to have active disease. This study was undertaken to determine whether the addition of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein (TNFR:Fc), to methotrexate therapy would provide additional benefit to patients who had persistent rheumatoid arthritis despite receiving methotrexate.
Methods: In a 24-week, double-blind trial, we randomly assigned 89 patients with persistently active rheumatoid arthritis despite at least 6 months of methotrexate therapy at a stable dose of 15 to 25 mg per week (or as low as 10 mg per week for patients unable to tolerate higher doses) to receive either etanercept (25 mg) or placebo subcutaneously twice weekly while continuing to receive methotrexate. The primary measure of clinical response was the American College of Rheumatology criteria for a 20 percent improvement in measures of disease activity (ACR 20) at 24 weeks.
Results: The addition of etanercept to methotrexate therapy resulted in rapid and sustained improvement. At 24 weeks, 71 percent of the patients receiving etanercept plus methotrexate and 27 percent of those receiving placebo plus methotrexate met the ACR 20 criteria (P<0.001); 39 percent of the patients receiving etanercept plus methotrexate and 3 percent of those receiving placebo plus methotrexate met the ACR 50 criteria (for a 50 percent improvement) (P<0.001). Patients receiving etanercept plus methotrexate had significantly better outcomes according to all measures of disease activity. The only adverse events associated with etanercept were mild injection-site reactions, and no patient withdrew from the study because of adverse events associated with etanercept.
Conclusions: In patients with persistently active rheumatoid arthritis, the combination of etanercept and methotrexate was safe and well tolerated and provided significantly greater clinical benefit than methotrexate alone.
Comment in
-
Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?N Engl J Med. 1999 Jan 28;340(4):310-2. doi: 10.1056/NEJM199901283400411. N Engl J Med. 1999. PMID: 9920958 No abstract available.
-
Etanercept in rheumatoid arthritis.N Engl J Med. 1999 Jun 24;340(25):2000; author reply 2001. doi: 10.1056/NEJM199906243402512. N Engl J Med. 1999. PMID: 10383273 No abstract available.
-
Etanercept in rheumatoid arthritis.N Engl J Med. 1999 Jun 24;340(25):2000; author reply 2001. N Engl J Med. 1999. PMID: 10383274 No abstract available.
-
Etanercept in rheumatoid arthritis.N Engl J Med. 1999 Jun 24;340(25):2000-1. N Engl J Med. 1999. PMID: 10383275 No abstract available.
Similar articles
-
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.Arthritis Rheum. 2003 Jun;48(6):1493-9. doi: 10.1002/art.11142. Arthritis Rheum. 2003. PMID: 12794815 Clinical Trial.
-
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.Arthritis Rheum. 2004 May;50(5):1412-9. doi: 10.1002/art.20221. Arthritis Rheum. 2004. PMID: 15146410 Clinical Trial.
-
Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.Ann Rheum Dis. 2006 Mar;65(3):328-34. doi: 10.1136/ard.2005.035709. Epub 2005 Aug 3. Ann Rheum Dis. 2006. PMID: 16079172 Free PMC article. Clinical Trial.
-
Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.Drugs. 2002;62(17):2493-537. doi: 10.2165/00003495-200262170-00013. Drugs. 2002. PMID: 12421111 Review.
-
Etanercept: a review of its use in rheumatoid arthritis.Drugs. 1999 Jun;57(6):945-66. doi: 10.2165/00003495-199957060-00014. Drugs. 1999. PMID: 10400407 Review.
Cited by
-
The Role of Etanercept in Controlling Clinical and Radiological Progression in Rheumatoid Arthritis: A Systematic Review.Cureus. 2024 Apr 12;16(4):e58112. doi: 10.7759/cureus.58112. eCollection 2024 Apr. Cureus. 2024. PMID: 38738082 Free PMC article. Review.
-
Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA.BMJ Open. 2024 Mar 12;14(3):e072300. doi: 10.1136/bmjopen-2023-072300. BMJ Open. 2024. PMID: 38479734 Free PMC article.
-
Sporadic Inclusion Body Myositis at the Crossroads between Muscle Degeneration, Inflammation, and Aging.Int J Mol Sci. 2024 Feb 27;25(5):2742. doi: 10.3390/ijms25052742. Int J Mol Sci. 2024. PMID: 38473988 Free PMC article. Review.
-
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis.Rheumatol Ther. 2024 Feb;11(1):61-77. doi: 10.1007/s40744-023-00618-1. Epub 2023 Nov 10. Rheumatol Ther. 2024. PMID: 37948030 Free PMC article.
-
Etanercept-associated episcleritis: a pediatric case report of a paradoxical adverse reaction and review of the literature.Clin Rheumatol. 2024 Feb;43(2):799-808. doi: 10.1007/s10067-023-06793-4. Epub 2023 Oct 17. Clin Rheumatol. 2024. PMID: 37845415 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous